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Key Points
• The UKALL-CNA
classifier is a validated
and robust prognostic
tool that can be
deployed in a variety of
clinical trial settings.
• The UKALL-CNA
classifier can be used
to refine risk stratifica-
tion for patients with
intermediate-risk
cytogenetics.
Genetic abnormalities provide vital diagnostic and prognostic information in pediatric acute
lymphoblastic leukemia (ALL) and are increasingly used to assign patients to risk groups.
We recently proposed a novel classifier based on the copy-number alteration (CNA) profile of
the 8 most commonly deleted genes in B-cell precursor ALL. This classifier defined 3 CNA
subgroups in consecutive UK trials and was able to discriminate patients with intermediate-
risk cytogenetics. In this study, we sought to validate the United Kingdom ALL (UKALL)–CNA
classifier and reevaluate the interaction with cytogenetic risk groups using individual
patient data from 3239 cases collected from 12 groups within the International BFM Study
Group. The classifier was validated and defined 3 risk groups with distinct event-free
survival (EFS) rates: good (88%), intermediate (76%), and poor (68%) (P , .001). There was
no evidence of heterogeneity, even within trials that used minimal residual disease to guide
therapy. By integrating CNA and cytogenetic data, we replicated our original key observation
that patients with intermediate-risk cytogenetics can be stratified into 2 prognostic subgroups.
Group A had an EFS rate of 86% (similar to patients with good-risk cytogenetics), while group
B patients had a significantly inferior rate (73%, P , .001). Finally, we revised the overall
genetic classification by defining 4 risk groups with distinct EFS rates: very good (91%),
good (81%), intermediate (73%), and poor (54%), P , .001. In conclusion, the UKALL-CNA
classifier is a robust prognostic tool that can be deployed in different trial settings and used to
refine established cytogenetic risk groups.
Submitted 5 September 2018; accepted 6 December 2018. DOI 10.1182/
bloodadvances.2018025718.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common type of
cancer in childhood. Survival rates in high-income countries have
improved from 10% in the 1960s to 90% in 2015.1 Although similar
improvements have been achieved in middle-income countries, the
absolute survival rates are lower (;75%).2 Treatment stratification
according to biological features and response has played an
important role in the improvement of survival rates. Despite these
improvements relapse remains the major clinical challenge in ALL.
Therefore, it is crucial to develop novel risk-stratification algorithms
to help ensure that each patient receives the appropriate type and
intensity of treatment to further increase survival rates and reduce
long-term side effects.
Chromosomal abnormalities are the hallmark of ALL and have
been widely used as prognostic markers. For example, in B-cell
precursor ALL (BCP-ALL), patients with high hyperdiploidy (51-65
chromosomes) or ETV6-RUNX1 have a favorable outcome,3
while patients with BCR-ABL1, KMT2A (MLL) rearrangements,
TCF3-HLF, intrachromosomal amplification of chromosome 21
(iAMP21), near haploidy (,30 chromosomes), or low hypodiploidy
(30-39 chromosomes) are associated with unfavorable outcomes
and require intensive treatment.4 The remaining patients, including
TCF3-PBX1, are usually classified as intermediate risk, and those
without an established chromosomal abnormality are referred to as
B-other ALL.3
Recent genome-wide analysis has shown that mutations and,
especially, copy-number alterations (CNAs) of genes involved in
B-cell differentiation, cell cycle regulation, transcription, prolifera-
tion, and cell survival are common in BCP-ALL.5,6 The most fre-
quently altered loci are EBF1, IKZF1, PAX5, CDKN2A/B, ETV6,
BTG1, RB1, and PAR1 (for detection of P2RY8-CRLF2). The
outcomes associated with these CNAs have been extensively
studied, and prognostic markers have been described among
them. For example, IKZF1 deletion, P2RY8-CRLF2 fusion, and
PAX5 amplification have been linked to poor outcomes in some
studies.7-14 However, there is evidence that the prognostic
effect of secondary abnormalities is context dependent and can
be modulated by the presence of other genetic abnormalities.
For example, the prognostic effect of IKZF1 deletions appears
worse when combined with BTG1 deletions or as a part of
the newly described IKZF1plus profile.15,16 Notably, IKZF1 deletions
do not adversely affect the good outcome associated with ERG
deletions.17 Therefore, it is important to analyze the effect of
different combinations of deletions and integrate them with other
risk factors.
In our previous study, we usedCNA data generated from consecutive
childhood treatment trials, UKALL97/99 and UKALL2003, to define
and validate a risk classifier (United Kingdom ALL [UKALL]–CNA).18
This classifier, which is based on the copy-number status of the 8
most commonly deleted regions in BCP-ALL, defined 3 CNA risk
groups. Here, we further validate the classifier using a total 3239
patients collected from 12 clinical study groups who are all members
of the International BFM (Berlin-Frankfurt-Munster) Study Group
(iBFM). We confirm the robustness of this classifier and demonstrate
how it interacts with cytogenetic and minimal residual disease (MRD)
risk groups. Finally, we propose a revised integrated cytogenetic and
CNA risk classification.
Methods
Patients
Patients eligible for this study were children and adolescents aged
1 to 19 years diagnosed with BCP-ALL before the end of 2014,
treated on a clinical trial, and tested by multiplex ligation–dependent
probe amplification (MLPA) using the SALSA P335 kit. All participat-
ing centers obtained local ethical committee approval and written
informed consent in accordance with the Declaration of Helsinki.
The demographic, clinical, genetic, and outcome data of the 3557
patients included were treated on 16 clinical trials collected from
12 study groups (supplemental Table 1). A total of 318 patients,
who did not meet the inclusion criteria or had incomplete data, were
excluded. Thus, 3239 patients, here after referred to as the iBFM
cohort, were available for analysis. The number of patients, their
recruitment period, follow-up time, and outcome varied among the
study groups (supplemental Figure 1A-D).
Classification of cases
Genetic abnormalities were characterized by one or more of
the following tests: cytogenetic analysis, fluorescence in situ
hybridization, reverse transcription polymerase chain reaction, single-
nucleotide polymorphisms, array or comparative genomic hybrid-
ization array. There was some variation in the distribution of cases
by cytogenetic risk group (supplemental Figure 1E), which was
driven by heterogeneous screening strategies. The high frequency
of B-other ALL in Brazil, Poland, JACLS ALL-02, and Russia is likely
due to the fact that not all cases were tested for all chromosomal
abnormalities.
The copy-number status of EBF1, IKZF1, PAX5, CDKN2A/B,
ETV6, BTG1, RB1, and PAR1 was determined using the SALSA
MLPA kit P335 (MRC Holland, Amsterdam, The Netherlands)
according to the manufacturer’s instructions. Each of these regions
was coded, by the contributing study groups, as per the original
study (see supplemental Methods)
We classified each patient in this cohort into 3 mutually exclusive
risk groups based on the cytogenetic results (Figure 1A)3 and
3 mutually exclusive risk groups according to the UKALL-CNA
classifier (Figure 1B),18 and we integrated the UKALL-CNA
classifier with cytogenetic risk groups to generate a 2-tier genetic
risk (Figure 1C).18
Statistical methods
As in the original study, we used event-free survival (EFS) as the
primary end point, defining it as the time from the start of treatment
to relapse, second tumor, or death, censoring at last contact and
quoting 5-year rates. Secondary end points, relapse rate and overall
survival, were considered but have not been presented, because
there was no discordance between the rates. Only a small number
of patients failed to achieve a complete remission (n 5 51) or had
a second tumor (n 5 27). Survival rates were calculated and com-
pared using Kaplan-Meier methods, log-rank tests, and univariate
Cox regression models. Stratified Cox models were used to
incorporate the effect of treatment risk group. Other comparisons
were performed using x2 or Fisher’s exact test as appropriate.
Forest plots were drawn to depict the heterogeneity (ie, variation)
in the effect between the study groups. Heterogeneity was
tested using Higgins’s I2 measure of inconsistency.19 Statistically
significant heterogeneity was defined as I2 $50% and a mild
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heterogeneity as between 25% and 50%. All tests were conducted
at the 5% significance level. All analyses were performed using
Intercooled Stata (StataCorp 2015 Stata Statistical Software
Release 14; StataCorp, College Station, TX) and R version 3.4.3
(http://www.R-project.org).
Results
Direct validation of the UKALL-CNA classifier and
genetic risk classification
Based on the copy-number status of the 8 defined loci, 106 unique
CNA profiles were observed in the iBFM cohort. The most frequent
CNA profile was “no deletions” and was observed in 40% of the
cases. Among the remaining CNA profiles, 93 were observed in
,1% of cases each, whereas only 5 profiles were present in $4%
of cases. These 5 CNA profiles were the isolated deletion of
CDKN2A/B (11%), ETV6 (7%), IKZF1 (4%), or PAX5 (4%) and the
concurrent deletion of PAX5 and CDKN2A/B (5%) (supplemental
Figure 2). There was a total of 29 new CNA profiles that had not
been observed in the original UK study.18 However, these profiles
were only observed in 45 cases and in total comprised ,0.1% of
cases. As per the original algorithm, cases with these profiles were
assigned to the CNA-IR group.18
Overall, the majority of patients (58%) had a CNA-GR profile, with
33% and 9% of cases harboring a CNA-IR and CNA-PR profile,
respectively (Figure 1B). The distribution of CNA risk groups varied
between the study groups and was driven by the difference in
frequency of regions specific alterations (supplemental Figure 1F).
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Figure 1. Definition of the cytogenetic, copy number
alteration and integrated classifications used in this study.
Definition of the classifiers used in the current study: cytogenetic
(A), UKALL-CNA (B), and original genetic risk (C). CYTO,
cytogenetic; GEN, genetics; GR, good risk; IR, intermediate risk;
PR, poor risk.
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However, within each study group, the CNA-GR profile was
the most prevalent (range, 50% to 72%), followed by CNA-IR
(range, 22% to 40%) and finally CNA-PR (range, 5% to 10%)
(supplemental Figure 1G). The UKALL-CNA classifier defined
patients with distinct EFS (Figure 2A). Patients with a CNA-GR
profile had a 50% reduced risk of an event compared with
patients with a CNA-IR profile (Table 1), whereas patients with a
CNA-PR profile had a 40% increased risk of an event compared
with CNA-IR patients (Table 1). There was no evidence of
heterogeneity across the 12 study groups for either comparison
(both I2 5 0) (Figure 2B).
MRD is also an important risk factor in pediatric ALL, and studies
have demonstrated the benefit of using MRD to determine
treatment intensity.20-22 Moreover, the prognostic effect of other
CNA and gene expression profiles, IKZF1plus and BCR-ABL1-like,
have been shown to be modulated by MRD.23,24 Therefore, we
reexamined the prognostic effect of the UKALL-CNA classifier
stratifying by protocol type (ie, whether or not treatment was
altered on the basis of MRD; MRD adapted vs non–MRD adapted)
(supplemental Table 1). Even among the 1753 patients treated on
MRD-adapted protocols, the UKALL-CNA classifier defined sub-
groups that were prognostic (supplemental Figure 3A). However,
the difference between CNA-IR and CNA-PR was not significant
(P 5 .08). As expected the UKALL-CNA classifier was highly prog-
nostic among the remaining 1486 patients treated on protocols
that did not alter treatment on the basis of MRD (supplemental
Figure 3B). The hazard ratios for CNA-GR vs CNA-IR and CNA-PR
vs CNA-IR did not differ according to the type of protocol (ie, MRD
adapted or not) (Table 1; Figure 2B). In addition, there was
no evidence of heterogeneity between different MRD-adapted
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Figure 2. Outcome of 3239 patients in the iBFM cohort
stratified by the UKALL-CNA classifier. (A-B) Kaplan-Meier
survival curves (A) and forest plots depicting the hazard ratio
and 95% CI from univariate Cox regression models comparing
the EFS for CNA-GR or CNA-PR against CNA-IR (B). Patients
in the Israeli National Study were excluded from the forest plot,
as no event occurred in the CNA-GR or CNA-IR groups.
DCOG, Dutch Childhood Oncology Group.
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protocols or between the remaining protocols (I25 0%) (Figure 2B).
Furthermore, stratifying by treatment risk group did not materially alter
the hazard ratios comparing the different subgroups (Table 1).
In our previous study,18 we integrated the newly defined CNA sub-
groups with classical cytogenetic risk groups (Figure 1C) to derive
2 genetic risk groups: GEN-GR and GEN-PR. Replicating this
definition on the iBFM cohort produced 2 subgroups comprising
71% and 29% cases, respectively. For most study groups, the
distribution of genetic risk groups was similar, except for Brazil, the
Israeli National study, and JACLS ALL-02 (supplemental Figure 1).
This variation was driven by incomplete screening strategies. Within
this cohort, GEN-GR patients had a significantly higher EFS rate
than GEN-PR patients (88% [86-89] vs 69% [66-72], P , .001)
(Figure 3A). GEN-PR patients were almost 3 times more likely to
suffer an event compared with GEN-GR patients (hazard ratio,
2.92; 95% CI, 2.46-3.47; P , .001). There was no evidence of
heterogeneity across the 12 study groups (I2 5 0). However, mild
heterogeneity in the hazard ratios was found between MRD-
adapted and non–MRD-adapted trials (I2 5 40%) (Figure 3B).
Prognostic effect of the UKALL-CNA classifier within
cytogenetic risk groups
We classified all patients in the iBFM cohort according to the
UK-defined cytogenetic risk groups.3 Overall, the 3 risk groups
comprised 48% (CYTO-GR), 46% (CYTO-IR), and 6%
(CYTO–high risk [HR]) of patients. The distribution of these risk
groups varied across the 12 study groups (supplemental Figure 1E),
reflecting the different definition of cytogenetic risk used by the study
groups according to their screening strategies. The majority of
CYTO-GR patients had a CNA-GRprofile (69%), while the remaining
patients were assigned to either CNA-IR (26%) or CNA-PR (5%). In
contrast, 50% CYTO-IR patients had a CNA-GR profile, while
patients in the remaining half were either CNA-IR (39%) or CNA-PR
(11%). Only 44% of CYTO-HR patients had a CNA-GR profile, while
38% and 18% of the patients had CNA-IR and CNA-PR profiles,
respectively (supplemental Figure 4).
Within the CYTO-GR group, the 3 CNA risk groups were
associated with significantly different EFS rates of 91% (89-93)
vs 85% (81-89) vs 73% (60-82) (P, .001) for CNA-GR vs CNA-IR
vs CNA-PR, respectively (Figure 4A). CYTO-GR/CNA-GR patients
had a 42% reduced risk of an event compared with those with
the CYTO-GR/CNA-IR (hazard ratio, 0.58; 95% CI, 0.42-0.81;
P5 .002). The CYTO-GR/CNA-PR patients had an 85% increased
risk of an event compared with CYTO-GR/CNA-IR patients (hazard
ratio, 1.85; 95% CI, 1.10-3.11; P 5 .02. Further subgroup
analysis revealed the same effect when ETV6-RUNX1 and high
hyperdiploidy patients were considered separately (supplemental
Figure 5). There was no evidence of heterogeneity across the 12
study groups for either the positive effect of CNA-GR or the
negative effect of CNA-PR within CYTO-GR patients (both I2 5 0).
However, when we analyzed these effects by protocol type (MRD
and non–MRD driven), we did observe significant (I2 5 72%) and
mild (I25 45%) heterogeneity, respectively (supplemental Table 2).
The beneficial effect of a CNA-GR profile was restricted to those
CYTO-GR patients treated on protocols that did not change
therapy on the basis of MRD. In contrast, the adverse effect of
a CNA-PR profile appeared to be limited to patients treated on
MRD-adapted protocols.
Among CYTO-IR patients, the EFS rates across the 3 CNA risk
groups was 86% (83-88), 74% (70-78), and 72% (64-79) for CNA-
GR, CNA-IR, and CNA-PR, respectively (Figure 4A). There was no
statistically significant difference between CYTO-IR/CNA-IR and
Table 1. Cox regression models comparing the risk of an event between different genetic ungroups defined by the UKALL-CNA and revised
genetic classifiers
Classifier
Overall MRD adapted Non–MRD adapted
Hazard ratio 95% CI P Hazard ratio 95% CI P Hazard ratio 95% CI P
Univariate models
UKALL-CNA
CNA-GR vs CNA-IR 0.48 0.40-0.57 ,.001 0.51 0.39-0.66 ,.001 0.45 0.35-0.58 ,.001
CNA-PR vs CNA-IR 1.43 1.12-1.82 .004 1.39 0.96-2.01 .08 1.42 1.03-1.96 .03
Genetic risk
GEN-GR vs GEN-VGR 1.68 1.29-2.19 ,.001 1.33 0.93-1.91 .12 2.19 1.46-3.29 ,.001
GEN-IR vs GEN-GR 2.05 1.65-2.53 ,.001 2.03 1.46-2.82 ,.001 2.03 1.53-2.69 ,.001
GEN-PR vs GEN-IR 1.95 1.51-2.53 ,.001 1.83 1.23-2.72 .003 2.13 1.51-3.01 ,.001
Models stratified by treatment risk group
UKALL-CNA
CNA-GR vs CNA-IR 0.53 0.44-0.64 ,.001 0.53 0.41-0.70 ,.001 0.52 0.41-0.67 ,.001
CNA-PR vs CNA-IR 1.31 1.02-1.66 .03 1.27 0.87-1.84 .22 1.33 0.97-1.83 .08
Genetic risk
GEN-GR vs GEN-VGR 1.62 1.24-2.12 ,.001 1.30 0.90-1.89 .16 2.06 1.37-3.09 .001
GEN-IR vs GEN-GR 1.86 1.50-2.31 ,.001 1.89 1.36-2.65 ,.001 1.82 1.37-2.42 ,.001
GEN-PR vs GEN-IR 1.36 1.02-1.81 .04 1.46 0.94-2.26 .09 1.36 0.94-1.99 .11
CI, confidence interval; VGR, very good risk.
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CYTO-IR/CNA-PR (P 5 .28). In our previous study, we combined
CYTO-IR/CNA-IR and CYTO-IR/CNA-PR patients (group B) and
compared their outcome to CYTO-IR/CNA-GR (group A).18
Replicating this analysis in the iBFM cohort revealed that group B
patients had a significantly inferior EFS at 5 years (P , .001,
Figure 5A) and were twice as likely to have an adverse event as
group A patients (hazard ratio, 2.09; 95% CI, 1.62-2.69; P, .001).
No evidence of heterogeneity was observed across the 12 study
groups or across the 2 main protocol types (MRD adapted and
non–MRD adapted) (Figure 5B).
There was no evidence of outcome heterogeneity by CNA profile
among patients with HR cytogenetics (ie, CYTO-HR) (58% [46-68]
vs 52% [38-63] vs 46% [27-63], P 5 .55, CNA-GR vs CNA-IR vs
CNA-PR, respectively) (Figure 4A).
A revised genetic risk classification for BCP-ALL
Visual inspection of the EFS curves of the 9 subgroups, which
resulted from integrating the UKALL-CNA and cytogenetic
subgroups (Figure 4A), revealed the presence of 4 discrete ge-
netic risk groups: GEN-VGR, GEN-GR, GEN-IR, and GEN-PR
(Figure 4B). These groups comprised 33%, 36%, 26% and
6% cases, respectively, and had significantly different outcomes
(Figure 4C). Patients in the GEN-VGR group, which comprised
patients with both GR cytogenetics and GR CNA features, had an
excellent EFS rate, which was significantly better than the EFS of
the remaining patients in the CYTO-GR group and the patients in
the CYTO-IR/CNA-IR group (GEN-GR). Thus, patients in the re-
vised GEN-GR group had a 68% higher risk of an event compared
with those patients in GEN-VGR group (Table 1). In contrast,
patients categorized in the GEN-IR group (composed mainly of
CYTO-IR patients who have a CNA-GR/IR profiles [91%] and
CYTO-GR patients who have CNA-PR profiles [9%]) had an EFS
rate of 73% (70% to 77%). This meant that GEN-IR patients were
twice as likely to suffer an event compared with GEN-GR patients
(Table 1). Patients in the GEN-PR group, comprised solely of
those patients with HR cytogenetics, were almost twice as likely
to have an event than GEN-IR patients (Table 1). Overall, there
was little evidence for heterogeneity across the participating
study groups (supplemental Table 4). However, there was mild
heterogeneity for the GEN-PR vs GEN-IR comparison (I2 5 37%),
but this was likely driven by small numbers. When we assessed
heterogeneity by protocol type (MRD adapted or non–MRD
adapted), we noted that the difference between the GEN-VGR
and GEN-GR groups was only seen for patients treated on
protocols that were non–MRD adapted (Table 1). This revised
genetic classification was validated in the original UK trial data-
sets (supplemental Figure 6; supplemental Table 3). Consistent
with the heterogeneity observed in the iBFM cohort, there was no
difference between the GEN-VGR and GEN-GR subgroups in
UKALL2003 (supplemental Figure 6B), which used MRD to adapt
therapy, compared with UKALL97/99 (supplemental Figure 6A),
which did not use MRD. Overall, adjusting for the effect of treatment
did not alter the prognostic impact of the revised genetic classifi-
cation (Table 1).
Discussion
The primary objective of this validation study was to assess whether
our previously defined UKALL-CNA classifier18 was prognostic in
non-UK treatment protocols. The results of our analysis clearly
demonstrated that the UKALL-CNA profile was indeed prognostic
across a range of treatment protocols used by 12 different study
groups (supplemental Figure 1). The hazard ratios, which measure
the relative risk of an event among the 3 CNA risk groups, derived
from the iBFM cohort were remarkably similar to those derived from
the 2 original cohorts. The hazard ratios for CNA-GR vs CNA-IR in
ALL97 and UKALL2003 were 0.48 (95% CI, 0.40-0.57; P , .001)
and 0.50 (95%CI, 0.40-0.64; P, .001), respectively. In addition, the
hazard ratios for CNA-PR vs CNA-IR were 1.43 (95% CI, 1.12-1.82;
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Figure 3. Outcome of 3239 patients in the iBFM cohort stratified by the original genetic risk group. (A-B) Kaplan-Meier survival curves (A) and forest plot (B)
depicting the hazard ratio and 95% confidence interval from univariate Cox regression models comparing the EFS for GEN-PR vs GEN-GR. Patients in the Israeli National
Study were excluded from the forest plot, as no event occurred in the GEN-GR group.
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P = .004) and 1.44 (95% CI, 1.04-1.99; P = .03), respectively.
Moreover, we demonstrated that the UKALL-CNA classifier provides
relevant prognostic information within both MRD-adapted and
non–MRD-adapted protocols (supplemental Figure 3). Pediatric
ALL protocols do not vary greatly in the core chemotherapeutic drugs
used or in the proportion of patients that receive a stem cell
transplant. However, they do differ in terms of risk stratification, drug
dosing, and scheduling. The study groups involved in this meta-
analysis span a wide range of countries across 4 continents and
18-year treatment period. Despite this extensive variation, the
prognostic relevance of the UKALL-CNA classifier was consistent
across different protocols and treatment risk groups (Table 1).
Therefore, we conclude that the UKALL-CNA classifier is a robust
tool for defining prognostic risk groups in pediatric BCP-ALL.
In addition to validating the UKALL-CNA classifier as a standalone
tool, we also investigated how it integrated with our published
cytogenetic risk groups.3 In our previous study, we showed that
the UKALL-CNA classifier did not add prognostic information to
the CYTO-GR or CYTO-HR groups. The results of this much
larger meta-analysis confirmed that patients in the CYTO-HR
group had a poor outcome irrespective of CNAs. However, in
contrast to the original study, we found significant outcome
heterogeneity by CNA profile among CYTO-GR patients (supple-
mental Table 2). The explanations for such a difference include
treatment period, screening strategies, and patient numbers.
However, given that the differences between CNA-GR and CNA-
IR were confined to non–MRD-adapted protocols, which were
generally from earlier time periods, it suggested that the difference
might have been caused by the iBFM cohort spanning a longer
treatment period compared with the original study (.20 vs ,15
years). We also observed a significantly inferior outcome for
CYTO-GR/CNA-PR patients compared with CYTO-GR/CNA-IR
patients (supplemental Table 2). Interestingly, this prognostic
effect was stronger among patients treated on MRD-adapted
protocols, supporting the notion that integrating MRD and ge-
netics improves risk prediction.24
We also validated the prognostic utility of the 2-tier genetic classi-
fication proposed in the UK study18 (Figure 3). The large number of
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Figure 4. Integration of cytogenetic and CNA subgroups using the 3239 patients in the iBFM cohort reveals a new genetic risk classification. (A) EFS of the 9
subgroups derived from cross-tabulating the 3 cytogenetic and 3 CNA risk groups. (B) Visualized inspection of these curves reveals 4 overall genetic risk groups. (C) EFS of
the revised genetic risk groups, which are significantly different from one another.
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patients collected enabled us to integrate cytogenetics with the
UKALL-CNA classifier in more depth, which defined 4 genetic risk
groups (Figure 4). The original GEN-GR group could be split into
VGR, GR, and IR groups, while the original GEN-PR group can be
divided into an IR and PR groups. There was little heterogeneity
across these revised risk groups by study group (supplemen-
tal Table 4). The mild heterogeneity observed for the GEN-PR
vs GEN-IR comparison could be explained by the incomplete
screening for HR cytogenetic abnormalities in some study groups
and also by treatment differences, which are more pronounced
for HR patients. There was significant heterogeneity comparing
the outcome of GEN-VGR vs GEN-GR patients by protocol type,
such that the improved outcome for GEN-VGR patients was
not observed in MRD-adapted protocols, including UKALL2003
(supplemental Figure 6). This finding is consistent with our observation
that within the CYTO-GR group, only CNA-GR patients treated
on a non–MRD-adapted protocol have a superior outcome to
CYTO-GR/CNA-IR patients (supplemental Table 2).
Our study has a number of strengths but also some limitations.
The major strengths are the number of cases collected and
breadth of contributing studies, including protocols that used
MRD to adapt treatment intensity. These 2 factors enabled us to
validate the UKALL-CNA classifier across a heterogeneous collec-
tion of protocols to confirm that its prognostic impact is robust.
However, as we collected data from so many study groups, we were
not able to collect and analyze the raw MLPA data. It is conceiv-
able that there was variation in the calling of deletions between
countries. Although there was variation in the frequency of deletions
across the 12 study groups (supplemental Figure 1) as well as between
the iBFM cohort and the original discovery cohort (supplemental
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Figure 5. Outcome of 1405 patients in the iBFM cohort
with IR cytogenetics classified according to their CNA
profile. (A-B) Kaplan-Meier survival curves (A) and forest plot
(B) depicting the hazard ratio and 95% confidence interval
from univariate Cox regression models comparing the EFS for
group B (CYTO-IR/CNA-IR and CYTO-IR/CNA-PR) vs group
A (CYTO-IR/CNA-GR). Patients in the Israeli National and
Sweden studies were excluded from the forest plot, as no
event occurred in group B.
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Table 3), it was not large, and there was no evidence of systematic
miscalling. Each study group followed the manufacturer’s guidelines,
called deletions according to the definition in the original study, and
mostly had experience of .100 MLPA tests. Discussions with the
contributing authors revealed only one significant area of variation
between groups, which was the calling of single probe loss. In line
with our original study, we did not consider single probe loss as
a deletion. However, this is an important question that must be
addressed when prospectively calling the CNA profile in future
studies. The main limitation of this meta-analysis was the reliance on
cytogenetic data derived from different testing strategies. Screening
for key prognostic chromosomal abnormalities, particularly those
associated with HR disease (eg, iAMP21), was not systemically
performed across study groups, which is in contrast to the original
UK study. Importantly, this did not affect the primary objective of
validating the UKALL-CNA classifier. We were careful to only
include patients in the B-other/CYTO-IR subgroups who had tested
negative for the most prevalent chromosomal abnormalities, so the
number of misclassified cases is likely to be small. We recognize
that exclusion of cases that had not been fully tested generated
relatively large B-other subgroups. However, because none of our
analyses were sensitive to the relative size of the 3 cytogenetic risk
groups, this did not impact the validity of our results. Although we
did not have individual patient MRD data, we validated the
classifiers by examining their effect in MRD adapted and non-
adapted trials separately as well as by stratifying by treatment risk
group. Both the UKALL-CNA and genetic classifiers were re-
markably stable highlighting the added benefit in MRD driven
protocols. The reduction in hazard ratio observed when we
compared GEN-PR and GEN-IR patients adjusting for treatment
(Table 1) is likely to be driven by HR patients receiving specific
interventions (eg, transplant).
The validation of the UKALL-CNA classifier confirms its wide-
spread clinical utility. Even though it is based on the 8 most
prevalent CNAs, it is conceivable that additional CNAs or profiles
could define additional information. Indeed the German and
Italian study groups have recently published a CNA profile termed
IKZF1plus.16 Patients are classified as IKZF1plus if they harbor an
IKZF1 deletion plus a deletion involving CDKN2A/B, PAX5, or
PAR1, unless they have a concurrent ERG deletion. The fre-
quency of IKZF1plus is ;6% among BCP-ALL patients, and it is
associated with a poor outcome in MRD-positive patients. Both
profiles highlight the prognostic importance of CNA in predicting
outcome in pediatric ALL. Moreover, there is a great deal of
similarity between the definition of IKZF1plus and the profiles
classified into the UKALL-CNA-PR group. While IKZF1plus de-
fines a small group of PR patients and is MRD dependent, the
UKALL-CNA classifier applies to all patients and defines 3 risk
groups that are prognostic even in MRD-adapted protocols.
One of the major advantages of the UKALL-CNA classifier is
the ability to subdivide the CYTO-IR cohort into subgroups with sig-
nificantly different outcomes (Figure 5). Importantly, and confirming
the findings of our original study, CYTO-IR/CNA-GR patients have
an outcome very similar to that of CYTO-GR patients. We have
recently shown that patients with both GR genetics and rapid
disease clearance have a very low risk of relapse.8,24 These
observations raise the possibility of defining a very large subset of
patients, which could be considered for treatment deescalation to
avoid future long-term toxicity.
In conclusion, we have validated the prognostic impact of the
UKALL-CNA classifier using a cohort of 3239 patients treated
on 16 trials including MRD-adapted protocols. This study adds
to the body of evidence that supports the prognostic effect
of secondary abnormalities in ALL. The integration of CNA
and cytogenetic risk group proves the context-dependent
nature of this effect and enables the definition of clinically
relevant genetic risk groups. We propose that these data support
the use of the UKALL-CNA classifier in future risk-stratification
algorithms.
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